


Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists

2/36





% INCREASE OF ⁴⁵ Ca


Docket No. A061CIP2 Application No.: Not Yet Assigned Inventor: MUNDY et al. Methods of Treating Multiple Myeloma a

Title: Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin Antagonists

3/36










Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists






7/36









Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.

Title: Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin Antagonists



Antagonists






FIG.12

13 / 36





FIG. 1

Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.


Title: Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin Antagonists

14/36




Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists

15/36





-1G. 15

16/36




7G. 16





19/36


1 (200 MICROGRAM) PS/2 TREATMENT / 1DAY N=3 / GROUP




2 (200 MICROGRAM) PS/2 TREATMENTS / 2DAYS N=3 / GROUP




6 (200 MICROGRAM) PS/2 TREATMENTS / 6DAYS N=5 / GROUP






Docket No. A061CIP2 Application No.: Not Yet Assigned Inventor: MUNDY et al. Title: Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin **Antagonists**

Antagonists




22/36



PERCENTAGE IGG2b CYTOPLASMIC PERCENTAGE IGG2b CYTOPLASMIC

Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists


23 / 36





the tends server server serve receives the court of the server server server server to the server se

The state of the s




5TGM1 CELLS (1E6) WERE INJECTED (I.V.) ON DAY O EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20 AND DAY 27


GROUPS N=3/GROUP


DISEASE FREE CONTROL
UNTREATED MYELOMA CONTROL
MELPHALAN TREATMENT--100 MICROGRAMS/INJECTION
PS/2 TREATMENT--100 MICROGRAMS/INJECTION
MELPHALAN AND PS/2
MELPHALAN AND rIGG2b ISOTYPE CONTROL

FIG. 25



25 / 36









FIG. 28

	DAY 20	DAY27
	PS/2 PLASMA LEVELS	PS/2 PLASMA LEVELS
8-PS/2	NONE DETECETED	NONE DECTECTED
9-P2/2	NONE DETECTED	NONE DETECTED
10-PS/2	NONE DETECTED	NONE DETECTED
11-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED
12-MELPHALAN+PS/2	3.7 µg/ml	NONE DETECTED
13-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED

29 / 36

FIG. 29




5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20


GROUPS N=2/GROUP

DISEASE FREE CONTROL

UNTREATED MYELOMA CONTROL
PS/2--100 MICROGRAMS/INJECTION
Sm.Mol. 8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg
Sm.Mol. 9257 CONTROL--3 mg/kg







Antagonists


32 / 36

FIG.32

7 **PS/2** 20 6 **PS/2** 8 PS/2 Sm. Mol. 1 PS/2 Sm. Mol. 16 PS/2 Sm. Mol. 5 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21 7 PS/2 WAS GIVÈN ON DAYS 15,16,17,18,19 AND 20 SMALL MOLECULE WAS GIVEN ON DAYS 15,16 AND 17 5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0 DAY


GROUPS N=2/GROUP


DISEASE FREE CONTROL UNTREATED MYELOMA CONTROL PS/2--100 MICROGRAMS/INJECTION 8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg 9257 CONTROL--3 mg/kg




34 / 36












The state of the s





O NO TREATMENT

ANT! α4Ab

MEL 100

MEL 100 + IgG

MEL 100 + ANT!α4Ab

Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists

THE STATE OF THE STREET ST